Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $165.83 USD
Change Today +6.66 / 4.18%
Volume 678.5K
BLUE On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

bluebird bio inc (BLUE) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/15 - $197.35
52 Week Low
10/15/14 - $29.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BLUEBIRD BIO INC (BLUE)

bluebird bio inc (BLUE) Related Businessweek News

No Related Businessweek News Found

bluebird bio inc (BLUE) Details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company also develops various CAR T cell products for liquid and solid tumor cancers. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

143 Employees
Last Reported Date: 02/25/15
Founded in 1992

bluebird bio inc (BLUE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $440.4K
Chief Financial Officer and Treasurer
Total Annual Compensation: $99.2K
Chief Operating Officer
Total Annual Compensation: $340.4K
Chief Medical Officer
Total Annual Compensation: $342.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $297.9K
Compensation as of Fiscal Year 2014.

bluebird bio inc (BLUE) Key Developments

bluebird bio, Inc.(NasdaqGS:BLUE) added to Russell 1000 Index

bluebird bio, Inc. has been added to Russell 1000.

bluebird bio, Inc.(NasdaqGS:BLUE) dropped from Russell 2000 Index

bluebird bio, Inc. will be removed from Russell 2000 Index

bluebird Seeks Acquisitions

bluebird bio, Inc. (NasdaqGS:BLUE) has filed a Follow-on Equity Offering in the amount of $400 million. bluebird may also use a portion of the net proceeds to in-license, acquire or invest in complementary gene therapy businesses, technologies, products or assets.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $165.83 USD +6.66

BLUE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $6.52 USD +0.18
Sangamo BioSciences Inc $9.15 USD +0.35
View Industry Companies

Industry Analysis


Industry Average

Valuation BLUE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 203.8x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 209.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at